Umbralisib, sold under the brand name Ukoniq, was an anti-cancer medication formulated as oral tablets. It is a kinase inhibitor that acts on phosphoinositide 3-kinase delta and casein kinase CK1-epsilon. It was originally indicated for adults with relapsed or refractory marginal zone lymphoma and follicular lymphoma who had already received prior systemic therapies. It was granted accelerated approval for medical use in the United States in February 2021, then withdrawn from the United States market in June 2022 after clinical trials identified an increased mortality risk, and it is no longer available in that market.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of Administration First Approved / Isolated Year Sources
1. Umbralisib (Wikipedia)
lead sentence 6
However, due to concerns for increased long term side effects leading to inferior overall survival which led to increased FDA scrutiny in the form of an ODAC review, it has been withdrawn from the US market.
https://en.wikipedia.org/wiki/Umbralisib, lead section
ne lymphoma (MZL) and follicular lymphoma (FL). It is taken by mouth.
View the Source2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code LQuote, First-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
3. Wikipedia
Wikipedia contributors, Wikimedia Foundation
4. Drugs.com: Ukoniq (umbralisib) FDA Approval History
FDA Approval HistoryQuote, FDA Approval History
Ukoniq (umbralisib) was first approved by the FDA on February 5, 2021
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.